Physician profile
James V Twede
NPI 1194818948
$5,570.28
in general payments reported to CMS, 2019-2025
36 companies · $1,201 in 2025
The $1,201 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $785 · 2020: $278 · 2021: $285 · 2022: $653 · 2023: $1,286 · 2024: $1,082 · 2025: $1,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,570.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $810.19 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $621.97 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $562.04 | 2020-2025 | Ilumya, Blu-U, Odomzo |
| Genzyme Corporation | $465.03 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $324.57 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $292.98 | 2019-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $271.89 | 2019-2025 | Adbry |
| Incyte Corporation | $250.49 | 2022-2025 | Opzelura |
| Ucb, INC. | $221.85 | 2022-2025 | Bimzelx, Cimzia |
| Amgen INC. | $199.04 | 2019-2025 | Otezla, Otezla |
| Lilly USA, LLC | $192.33 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $182.98 | 2019-2025 | Jublia, Cabtreo |
| Genentech USA, INC. | $138.61 | 2019 | |
| Galderma Laboratories, L.P. | $113.35 | 2019-2025 | Nemluvio, Aklief |
| Organogenesis INC. | $102.82 | 2022-2025 | Puraply Wound Matrix, Affinity |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $89.68 | 2019-2021 | |
| Almirall LLC | $78.24 | 2019-2025 | Klisyri |
| Biofrontera INC. | $68.64 | 2023-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.33 | 2023-2024 | Spevigo |
| Dermavant Sciences, INC. | $60.24 | 2023-2024 | Vtama |
| Mimedx Group, INC. | $52.90 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $51.80 | 2022-2023 | Seglentis |
| Mylan Institutional INC. | $48.33 | 2023 | Hulio |
| Blueprint Medicines Corporation | $41.20 | 2024 | Ayvakit |
| Dermira, INC. | $31.93 | 2019 | |
| Mayne Pharma Commercial LLC | $30.61 | 2019 | |
| Journey Medical Corporation | $30.34 | 2019 | |
| Biocon Biologics INC | $29.12 | 2023 | Hulio |
| Organon LLC | $23.65 | 2025 | |
| Strata Skin Sciences, INC. | $22.57 | 2024 | Xtrac |
| Pfizer INC. | $19.89 | 2022 | |
| Celgene Corporation | $18.34 | 2019 | |
| Mission Pharmacal Company | $18.24 | 2019 | |
| Kyowa Kirin, INC. | $16.44 | 2025 | |
| Arcutis Biotherapeutics, INC. | $13.53 | 2024 | Zoryve |
| Mylan Pharmaceuticals INC. | $13.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Twede listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.